Alpha Cognition Income from Continuous Operations 2020-2024 | ACOG
Alpha Cognition income from continuous operations from 2020 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Alpha Cognition Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-14 |
| 2022 |
$-12 |
| 2021 |
$-20 |
| 2020 |
$-6 |
| 2019 |
$-7 |
Alpha Cognition Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-06-30 |
$-2 |
| 2024-03-31 |
$-5 |
| 2023-12-31 |
$-6 |
| 2023-09-30 |
$-3 |
| 2023-06-30 |
$-3 |
| 2023-03-31 |
$-2 |
| 2022-12-31 |
$-4 |
| 2022-09-30 |
$-2 |
| 2022-06-30 |
$-3 |
| 2022-03-31 |
$-3 |
| 2021-12-31 |
$-3 |
| 2021-09-30 |
$-4 |
| 2021-06-30 |
$0 |
| 2021-03-31 |
$-12 |
| 2020-12-31 |
$-2 |
| 2020-09-30 |
$-1 |
| 2020-06-30 |
$-2 |
| 2020-03-31 |
$-1 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.035B |
$0.000B |
|
Alpha Cognition Inc. is a clinical stage biopharmaceutical company. It involved in developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. Alpha Cognition Inc. is based in Vancouver, British Columbia.
|
